Related Experiment Video
Updated: Jun 20, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years
Daniela Poli1, Emilia Antonucci, Elisa Grifoni
1Department of Medical and Surgical Critical Care, University of Florence, Florence, Italy. polida@aou-careggi.toscana.it
Insights
Elderly patients with atrial fibrillation (AF) on oral anticoagulant treatment (OAT) face bleeding risks, but careful management can maintain low rates. Age over 80 increases major hemorrhage risk, highlighting the need for vigilant anticoagulation control.
Area of Science:
- Cardiology
- Geriatrics
- Pharmacology
Background:
- Stroke prevention in atrial fibrillation (AF) is critical, especially for individuals aged 80 years and older.
- Oral anticoagulant treatment (OAT) is a key strategy for AF-related stroke prevention.
- Understanding bleeding risks in elderly AF patients is essential for optimizing treatment.
Purpose of the Study:
- To evaluate bleeding rates in relation to patient age (categorized as <80 and ≥80 years).
- To assess the impact of anticoagulation quality, measured by time in therapeutic range (TTR), on bleeding events.
- To identify specific factors associated with bleeding complications in AF patients on OAT.
Main Methods:
- A prospective observational study involving 783 patients with AF receiving OAT.
- Data collection included patient demographics, anticoagulation quality (TTR), and bleeding event occurrences.
- Statistical analyses, including Cox regression, were used to determine risk factors for bleeding.
Main Results:
- Patients spent a median of 71% of time within the international normalized ratio therapeutic range.
- No significant difference in OAT quality was observed between younger (<80) and older (≥80) age groups.
- The overall bleeding rate was 3.7 per 100 patient-years, with major hemorrhage rates of 1.4 per 100 patient-years.
- Patients aged ≥80 years had a higher rate of major hemorrhage (1.9 vs. 0.9 per 100 patient-years; p=0.004).
- A history of previous cerebral ischemic events (OR: 2.5) and age ≥80 years (OR: 2.0) were independently associated with increased bleeding risk.
Conclusions:
- Major bleeding complications can be maintained at acceptably low levels in very elderly AF patients on OAT.
- Careful management and optimization of anticoagulation are crucial for minimizing bleeding risks.
- Age and a history of ischemic events are significant predictors of bleeding in this population, necessitating closer monitoring.
Objectives:
We sought to evaluate the rate of bleeding in relation to age (<80 and > or =80 years), the quality of anticoagulation (expressed as time spent in international normalized ratio therapeutic range), and factors associated with bleeding events.
Background:
Stroke prevention in patients with atrial fibrillation (AF) is an increasingly crucial public health target, particularly in patients ages > or =80 years.
Methods:
We conducted a prospective observational study on 783 patients with AF on oral anticoagulant treatment (OAT).
Results:
Patients spent a median 14%, 71%, and 15% of time below, within, and above the intended therapeutic range, respectively. No difference in OAT quality was found between patients age <80 and > or =80 years. During follow-up, 94 patients experienced bleeding complications (rate 3.7 x 100 patient/years), 37 major (rate 1.4 x 100 patient/years), and 57 minor (rate 2.2 x 100 patient/years). Different rates of major hemorrhage were observed between patients age <80 and > or =80 years (0.9 vs. 1.9 x 100 patient/years; p = 0.004). Bleeding risk also was greater in patients with a history of previous cerebral ischemic event (odds ratio [OR]: 2.5; 95% confidence interval: 1.3 to 4.8; p = 0.007). A Cox regression analysis confirmed age > or =80 years associated with bleeding risk (OR: 2.0).
Conclusions:
These results indicate that the rate of major bleeding complications may be kept acceptably low also in very elderly AF patients on OAT, provided a careful management of anticoagulation is obtained.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Venous Thrombosis IV: Nursing Management
01:29Venous Thrombosis III: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
01:24Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.